MX2020011542A - Inhibidores de cd73. - Google Patents

Inhibidores de cd73.

Info

Publication number
MX2020011542A
MX2020011542A MX2020011542A MX2020011542A MX2020011542A MX 2020011542 A MX2020011542 A MX 2020011542A MX 2020011542 A MX2020011542 A MX 2020011542A MX 2020011542 A MX2020011542 A MX 2020011542A MX 2020011542 A MX2020011542 A MX 2020011542A
Authority
MX
Mexico
Prior art keywords
inhibitors
compounds
compositions
infections
cancer
Prior art date
Application number
MX2020011542A
Other languages
English (en)
Inventor
John Eksterowicz
Daqing Sun
Liusheng Zhu
Hiroyuki Kawai
Xiaohui Du
Yosup Rew
Valeria R Fantin
Brian R Blank
Jared Moore
Qiuping Ye
Tatiana Zavorotinskaya
Kejia Wu
Johnny Pham
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of MX2020011542A publication Critical patent/MX2020011542A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se describen inhibidores de CD73 y las composiciones farmacéuticas que comprenden estos compuestos. Los compuestos y composiciones de la invención son útiles para el tratamiento de cáncer, infecciones y enfermedades neurodegenerativas.
MX2020011542A 2018-04-30 2019-04-30 Inhibidores de cd73. MX2020011542A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862664841P 2018-04-30 2018-04-30
US201862737647P 2018-09-27 2018-09-27
US201862757714P 2018-11-08 2018-11-08
US201862777697P 2018-12-10 2018-12-10
US201962810790P 2019-02-26 2019-02-26
PCT/US2019/030068 WO2019213174A1 (en) 2018-04-30 2019-04-30 Cd73 inhibitors

Publications (1)

Publication Number Publication Date
MX2020011542A true MX2020011542A (es) 2020-11-24

Family

ID=68386646

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011542A MX2020011542A (es) 2018-04-30 2019-04-30 Inhibidores de cd73.
MX2023002507A MX2023002507A (es) 2018-04-30 2020-10-29 Inhibidores de cd73.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002507A MX2023002507A (es) 2018-04-30 2020-10-29 Inhibidores de cd73.

Country Status (13)

Country Link
US (3) US11325938B2 (es)
EP (1) EP3787635A4 (es)
JP (2) JP7489323B2 (es)
KR (1) KR20210018255A (es)
CN (1) CN112423764A (es)
AU (1) AU2019261976A1 (es)
BR (1) BR112020022068A2 (es)
CA (1) CA3098493A1 (es)
IL (1) IL304348B2 (es)
MX (2) MX2020011542A (es)
SG (1) SG11202010790XA (es)
TW (1) TW202014182A (es)
WO (1) WO2019213174A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
JP7489323B2 (ja) 2018-04-30 2024-05-23 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
US20210253614A1 (en) * 2018-05-31 2021-08-19 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
JP7538047B2 (ja) * 2018-06-21 2024-08-21 アンテンジーン セラピューティクス リミテッド エクトヌクレオチダーゼ阻害剤及びその使用方法
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
CN116854758A (zh) * 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂
EP4353732A1 (en) 2021-05-11 2024-04-17 Xizang Haisco Pharmaceutical Co., Ltd. Small molecular cd73 antagonist and use thereof
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
US20240140980A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
CN116217644B (zh) * 2023-04-24 2023-08-08 南京颐媛生物医学研究院有限公司 抗冠状病毒核糖核苷类化合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
CA2429352A1 (en) 2000-12-15 2002-06-20 Lieven Stuyver Antiviral agents for treatment of flaviviridae infections
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
US10654884B2 (en) 2014-04-25 2020-05-19 Boehringer Ingelheim International Gmbh Purine derivatives as CD73 inhibitors for the treatment of cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
WO2017098421A1 (en) * 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
EP3399984B1 (en) 2016-01-08 2023-09-06 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
CN110234656B (zh) * 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
EP3541396A4 (en) 2016-11-18 2020-07-22 Arcus Biosciences, Inc. CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS
US10570167B2 (en) 2016-12-22 2020-02-25 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
JP2020515559A (ja) * 2017-03-31 2020-05-28 ぺロトン セラピューティクス，インク． Ｃｄ７３阻害剤とその使用
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
JP7489323B2 (ja) 2018-04-30 2024-05-23 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
US20210253614A1 (en) 2018-05-31 2021-08-19 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
JP7538047B2 (ja) 2018-06-21 2024-08-21 アンテンジーン セラピューティクス リミテッド エクトヌクレオチダーゼ阻害剤及びその使用方法
EP3843714A4 (en) 2018-08-27 2022-04-20 Arcus Biosciences, Inc. CD73 INHIBITORS
US20220363709A1 (en) 2019-06-20 2022-11-17 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
WO2021011689A1 (en) 2019-07-16 2021-01-21 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂

Also Published As

Publication number Publication date
WO2019213174A1 (en) 2019-11-07
EP3787635A4 (en) 2022-03-02
JP7489323B2 (ja) 2024-05-23
US20220220147A1 (en) 2022-07-14
EP3787635A1 (en) 2021-03-10
IL304348B1 (en) 2024-04-01
US20210047359A1 (en) 2021-02-18
US11807658B2 (en) 2023-11-07
TW202014182A (zh) 2020-04-16
IL304348B2 (en) 2024-08-01
AU2019261976A1 (en) 2020-12-03
MX2023002507A (es) 2023-03-13
CA3098493A1 (en) 2019-11-07
JP2021522280A (ja) 2021-08-30
IL304348A (en) 2023-09-01
CN112423764A (zh) 2021-02-26
US20240124512A1 (en) 2024-04-18
BR112020022068A2 (pt) 2021-04-20
KR20210018255A (ko) 2021-02-17
SG11202010790XA (en) 2020-11-27
JP2024112864A (ja) 2024-08-21
US11325938B2 (en) 2022-05-10

Similar Documents

Publication Publication Date Title
MX2023002507A (es) Inhibidores de cd73.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2022005256A (es) Inhibidores de cd73.
MX2020013881A (es) Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen.
PH12018501920B1 (en) Bromodomain inhibitors
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12019502646A1 (en) Pyrazole magl inhibitors
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
MX2020000135A (es) Nuevos compuestos de quinolinona.
EP3868385A4 (en) GASTRIC CANCER TREATMENT COMPOSITION INCLUDING A SYT11 INHIBITOR AS AN ACTIVE INGREDIENT
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
WO2018211324A8 (en) Prodrugs for the treatment of disease
EP3897602A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
TN2021000092A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EP3820477A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
WO2019157225A3 (en) Certain chemical entities, compositions, and methods
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
MX2020002812A (es) Abx196 para usarse en el tratamiento del cancer de vejiga.
EP3782620A4 (en) PHARMACEUTICAL COMPOSITION WITH A DERIVATIVE COMPOUND OF 1,2-NAPHTHOQUINONE FOR THE PREVENTION OR TREATMENT OF SOLID CANCER OR BLOOD CANCER